ABCL AbCellera Biologics Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:54
May 26
May 26
ABCL is a buy at current levels with acknowledged downside risk to mid-$4s; author recommends DCA or tranched entry to manage volatility rather than a single full position.
MED
09:27
May 26
May 26
Author discloses AbCellera Biologics as one of three concentrated primary holdings, characterizing it as a generational long-term position with no specific near-term catalyst stated.
MED
01:23
May 24
May 24
Buy ABCL targeting a rapid rerating to ~$10, with a potential dip to mid/high $4s offering an attractive entry point; speaker expresses conviction on upside but reasoning behind the rerating catalyst is not specified.
MED
15:15
May 21
May 21
Names ABCL a cornerstone of his portfolio for future generational wealth.
HIGH
14:35
May 21
May 21
ABCL sub-$4 a gift: good phase 1 data, digital-biology narrative, strong team, non-dilutive, trading at book value gives conviction.
HIGH
19:13
May 12
May 12
ABCL is his bet on 'digital biology' rerating: real products/revenue, no debt, low dilution, long cash runway — expects rapid rerate this year.
HIGH
23:44
May 11
May 11
His highest-conviction trade (long & short term): AI antibody platform, first phase 1 results validated, actual revenue-producing company.
HIGH
20:30
May 09
May 09
ABCL has no debt, trades near book value with a large cash position, proven antibody track record, and a near-term phase 1/2 data catalyst Monday.
MED
09:31
May 09
May 09
Loves the company, likes that it trades near book value, and expects Monday's data report to be a major catalyst.
HIGH
14:56
May 04
May 04
Took ABCL position as counter to ABSI; ABCL generates antibodies vs known epitopes and is breaking out technically.
HIGH
About ABCL Analyst Coverage
Buzzberg tracks ABCL (AbCellera Biologics Inc.) across 1 sources. 12 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (86%). 14 total trade ideas tracked.